To delineate RAS signaling in response to MEK inhibition, we employed RPPA, a sensitive, high-throughput, functional proteomic technology that offers many of the advantages needed to quantify proteins in the normal and tumor tissues of CRC patients45,46. This evidence concerns the gene MAP2K7 and colorectal carcinoma.